Study of Bronchiectasis and Associated Cardiovascular Comorbidities

Study Overview
=================
Brief Summary
-----------------
Effect of cardiovascular comorbidities on disease severity and quality of life in Patients with acute exacerbation of non-cystic fibrosis bronchiectasis

Detailed Description
-----------------
The study will include patients with bronchiectasis, and in an attempt to correlate the effect and burden of cardiovascular comorbidities in those patients, we will study the quality of life in those patients in comparison to the control group ( patients with bronchiectasis and without any other comorbidities) using SF-36 quality of life questionnaire. We will also study the inflammatory markers in both groups using D-dimer, BNP, and CRP and correlate them with the frequency of hospital admission, the severity of symptoms, and the general health state.

Official Title
-----------------
Effect of Cardiovascular Comorbidities on Disease Severity and Quality of Life in Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis

Conditions
-----------------
Bronchiectasis

Intervention / Treatment
-----------------
* Device: Echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Any Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period. Exclusion Criteria: Any Patients who refuse to participate in the study. Any other comorbidity or end-organ failure may affect the study's result.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with bronchiectasis and cardiovascular comorbidities<br>Patients with Bronchiectasis had no comorbidities other than cardiovascular comorbidities during the study period. | Device: Echocardiography<br>* echocardiographic study of both groups<br>* Other names: Routine laboratory investigations and inflammatory markers;|
| Patients with bronchiectasis and without cardiovascular comorbidities<br>Patients with Bronchiectasis had no comorbidities. | Device: Echocardiography<br>* echocardiographic study of both groups<br>* Other names: Routine laboratory investigations and inflammatory markers;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assessment of BNP (Brain natriuretic peptide) pg/ml levels in patients with bronchiectasis and cardiovascular comorbidities. | Serum BNP (Brain natriuretic peptide) pg/ml will be compared in both groups. | March 2023 to September 2023 | 
| Assessment of Quality of life in patients and control groups using The Short Form (36) Health Survey (SF-36) | The Short Form (36) Health Survey will be performed in both groups. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. | March 2023 to September 2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospitalization frequency in patient group compared to control group. | Number of hospital admission in the last year will be compared in both groups. | March 2023 to September 2023 |